Diabetes Technology & Therapeutics

Papers
(The H4-Index of Diabetes Technology & Therapeutics is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Acknowledgment of Reviewers 2025194
New Insulins, Biosimilars, and Insulin Therapy105
Practical Application of Continuous Glucose Monitoring in Clinical Practice: Case Studies105
Statistically Adjusting for Wear Time in Randomized Trials of Continuous Glucose Monitors as a Complement to Intent-to-Treat and As-Treated Analyses: Application and Evaluation in Two Trials78
Impact of Sample Type on ADAP-Based Autoantibody Detection for Type 1 Diabetes Population Screening77
Raising the Bar: High Time in Range During the First Year of Diagnosis of Type 1 Diabetes in Children and Adolescents Using Automated Insulin Delivery with Intense Support76
Glycemia Around Exercise in Adults with Type 1 Diabetes Using Automated and Nonautomated Insulin Delivery Pumps: A Switch Pilot Trial70
Disordered Eating Behaviors Among Adolescents and Young Adults with Type 1 Diabetes Treated with Insulin Pumps and Hybrid Closed-Loop Systems70
Predicting Risk for Diabetic Ketoacidosis in Children Recently Diagnosed with Type 1 Diabetes Using the Risk Index for Diabetic Ketoacidosis67
The Official Journal of ATTD Advanced Techologies & Treatments for Diabetes CONFERENCE 6–9 MARCH 2024 I FLORENCE & ONLINE67
Letter: Response to: “Lack of Association Between Hemoglobin A1c and Continuous Glucose Monitor Metrics Among Individuals with Prediabetes and Normoglycemia”64
Is It Time to Replace Time-in-Range with Time-in-Tight-Range? Maybe Not60
Real-Life Achievements of MiniMed 780G Advanced Closed-Loop System in Youth with Type 1 Diabetes: AWeSoMe Study Group Multicenter Prospective Trial60
Rebound Hyperglycemia in Children and Adolescents with Type 1 Diabetes Using Automated Insulin Delivery Systems60
Safety and Functionality of a Novel Clinical Decision-Support Algorithm with Insulin Efsitora Alfa in Adults with Type 2 Diabetes: Early Feasibility Study59
Letter: Tirzepatide in Type 1 Diabetic Obese Patient Using Hybrid Closed-Loop59
MiniMed ™ 780G System Users Achieve Similar Glycemic Outcomes Regardless of Socioeconomic Disadvan57
Developing and Evaluating a Natural Language Processing Algorithm to Detect Insulin Pump and Continuous Glucose Monitor Use in Electronic Health Records of Patients with Type 1 Diabetes56
Decision Support Tool for Self-Management of Insulin Dosing in Type 1 Diabetes with Multiple Daily Injections: A Proof-of-Concept Study52
Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States51
A Glycemic Status Classification Model Using a Radiofrequency Noninvasive Blood Glucose Monitor50
Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin49
Acknowledgment of Reviewers: 202449
Relationship Between Moderate-to-Vigorous Physical Activity and Glycemia Among Young Adults with Type 1 Diabetes and Overweight or Obesity: Results from the Advancing Care for Type 1 Diabetes and Obes44
Dosing Afrezza: It’s Not that Complicated43
Case Reports: Practical Use of Pulmonary Inhaled (Technosphere) Insulin in Type 1 Diabetes, Type 2 Diabetes, and Pregnancy42
The Future of Dual Glucose–Ketone Monitoring in Youth with Diabetes41
A Call-to-Action to Eliminate Barriers to Accessing Automated Insulin Delivery Systems for People with Type 1 Diabetes40
Practical Considerations and Implementation of Automated Insulin Delivery Systems40
Glucose Predictions Improve Glycemic Control: A Digital Twin Evaluation39
Software Packages and Tools for the Analysis of Continuous Glucose Monitoring Data39
A Retrospective Real-Life Study to Compare Glycemic Control Between Simplified Meal Size Estimation and Precise Carbohydrates Counting in Type 1 Diabetes Patients Using DBLG1 Hybrid Closed-Loop System38
Automated Insulin Delivery with Remote Real-Time Continuous Glucose Monitoring for Hospitalized Patients with Diabetes: A Multicenter, Single-Arm, Feasibility Trial38
Clinical Impact of Continuous Glucose Monitoring in Noninsulin Treated Type 2 Diabetes: A Review37
Beyond the Coefficient of Variation: Reframing Glycemic Variability as Dispersion and Volatility37
Is It Time to Move Beyond TIR to TITR? Real-World Data from Over 20,000 Users of Continuous Glucose Monitoring in Patients with Type 1 and Type 2 Diabetes37
A Randomized Crossover Pilot Study Evaluating Glucose Control During Exercise Initiated 1 or 2 h After a Meal in Adults with Type 1 Diabetes Treated with an Automated Insulin Delivery System37
0.07731294631958